10x Genomics Statistics
Want to see TXG full AI Analyst Report?
10x Genomics (TXG) Stock Statistics & Valuation Metrics
Total Valuation
10x Genomics has a market cap or net worth of $7.23B. The enterprise value is $11.32B.
- Market Cap
- $7.23B
- Enterprise Value
- $11.32B
Share Statistics
10x Genomics has 121,455,315 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 121,455,315
- Owned by Insiders
- 2.21%
- Owned by Institutions
- 85.61%
Financial Efficiency
10x Genomics’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is -12.34%.
- Return on Equity (ROE)
- -0.05
- Return on Assets (ROA)
- -0.04
- Return on Invested Capital (ROIC)
- -12.34%
- Return on Capital Employed (ROCE)
- -0.12
- Revenue Per Employee
- 545.69K
- Profits Per Employee
- -36.96K
- Employee Count
- 1,178
- Asset Turnover
- 0.62
- Inventory Turnover
- 3.53
Valuation Ratios
The current PE Ratio of 10x Genomics is -106.38. 10x Genomics’s PEG ratio is 0.23.
- PE Ratio
- -106.38
- PS Ratio
- 10.86
- PB Ratio
- 8.63
- Price to FCF
- 71.65
- Price to Operating Cash Flow
- 72.57
- PEG Ratio
- 0.23
Income Statement
In the last 12 months, 10x Genomics had revenue of 642.82M and earned -43.54M in profits. Earnings per share was -0.35.
- Revenue
- 642.82M
- Gross Profit
- 443.88M
- Operating Income
- -110.89M
- Pretax Income
- -39.91M
- Net Income
- -43.54M
- EBITDA
- 3.91M
- Earnings Per Share (EPS)
- -0.35
Cash Flow
In the last 12 months, operating cash flow was 99.70M and capital expenditures -5.93M, giving a free cash flow of 93.77M billion.
- Operating Cash Flow
- 99.70M
- Free Cash Flow
- 93.77M
- Free Cash Flow per Share
- 0.72
Dividends & Yields
10x Genomics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 1.40%
- Earnings Yield
- -0.93%
Stock Price Statistics
- Beta
- 1.73
- 52-Week Price Change
- 246.07%
- 50-Day Moving Average
- 73.92
- 200-Day Moving Average
- 42.90
- Relative Strength Index (RSI)
- 36.72
- Average Volume (3m)
- 3.38M
Important Dates
10x Genomics upcoming earnings date is Feb 17, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Feb 17, 2027
- Ex-Dividend Date
- ―
Financial Position
10x Genomics as a current ratio of 4.46, with Debt / Equity ratio of 19.81%
- Current Ratio
- 4.46
- Quick Ratio
- 4.09
- Debt to Market Cap
- 0.04
- Net Debt to EBITDA
- -80.90
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, 10x Genomics has paid 3.64M in taxes.
- Income Tax
- 3.64M
- Effective Tax Rate
- -0.09
Enterprise Valuation
10x Genomics EV to EBITDA ratio is 139.50, with an EV/FCF ratio of 66.42.
- EV to Sales
- 10.07
- EV to EBITDA
- 139.50
- EV to Free Cash Flow
- 66.42
- EV to Operating Cash Flow
- 62.47
Balance Sheet
10x Genomics has $575.68M in cash and marketable securities with $75.79M in debt, giving a net cash position of $499.89M billion.
- Cash & Marketable Securities
- $575.68M
- Total Debt
- $75.79M
- Net Cash
- $499.89M
- Net Cash Per Share
- $4.12
- Tangible Book Value Per Share
- $5.91
Margins
Gross margin is 71.88%, with operating margin of -11.67%, and net profit margin of -10.84%.
- Gross Margin
- 71.88%
- Operating Margin
- -11.67%
- Pretax Margin
- -10.53%
- Net Profit Margin
- -10.84%
- EBITDA Margin
- 7.22%
- EBIT Margin
- 0.24%
Analyst Forecast
The average price target for 10x Genomics is $74.15, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $74.15
- Price Target Upside
- 34.85% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 15
- Revenue Growth Forecast
- -3.62%
- EPS Growth Forecast
- 16.67%
Scores
- Smart Score
- 1
- AI Score
- 57

